Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

OBJECTIVE: Evaluation of the comparative effectiveness of enzalutamide and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) is limited to meta-analyses of randomized trials that exclude patients with significant comorbidities. We evaluated overall survival (OS) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagawa, Scott T., Ramaswamy, Krishnan, Huang, Ahong, Mardekian, Jack, Schultz, Neil M., Wang, Li, Sandin, Rickard, Lechpammer, Stanislav, George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616757/
https://www.ncbi.nlm.nih.gov/pubmed/33612825
http://dx.doi.org/10.1038/s41391-021-00318-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616757/
https://www.ncbi.nlm.nih.gov/pubmed/33612825
http://dx.doi.org/10.1038/s41391-021-00318-3

Ejemplares similares